Skip to main content
OpenTrials

Clinical trial condition

Skin Diseases, Papulosquamous

Explore clinical trials studying Skin Diseases, Papulosquamous. Study availability and eligibility vary by location and protocol.

1,740 public trials 205 recruiting studies
Refine in advanced search Browse all conditions

Skin Diseases, Papulosquamous trial results

Completed

Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis

NCT00521339

Conditions
Plaque-type Psoriasis, Psoriasis, Psoriasis-Type Psoriasis, +3 more
Locations
  • Tufts-New England Medical Center Hospitals Boston, Massachusetts, United States
  • Central Dermatology St Louis, Missouri, United States
  • Oregon Medical Research Center, P.C. Portland, Oregon, United States
  • Baylor Research Institute Dallas, Texas, United States
View Trial Details
Completed

Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Patients With Moderate-To-Severe Plaque-Type Psoriasis

NCT01988103

Conditions
Arthritis, Arthritis, Psoriatic, Bone Diseases, +12 more
Locations
  • Ekihigashi Hifuka Clinic Fukuoka, Japan
  • Tsutsui Clinic Dermatology & Plastic Surgery Fukuoka, Japan
  • Yano Hifuka Hinyokika Clini Fukuoka, Japan
  • Fukuoka University Hospital Fukuoka, Japan
View all 56 locations
View Trial Details
Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of CC-90006 in Subjects With Mild to Moderate Plaque-type Psoriasis

NCT03337022

Conditions
Psoriasis, Skin Diseases, Skin Diseases, Papulosquamous, +1 more
Locations
  • Anaheim Clinical Trials, LLC Anaheim, California, United States
  • TKL Research Fair Lawn, New Jersey, United States
  • Altoona Center for Clinical Research Duncansville, Pennsylvania, United States
  • Innovaderm Research Montreal, Quebec, Canada
View Trial Details
Completed

PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis

NCT01212770

Conditions
Arthritis, Arthritis, Psoriatic, Bone Diseases, +14 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Elite Clinical Studies, LLC Phoenix, Arizona, United States
  • Catalina Pointe Clinical Research Incorporated Tucson, Arizona, United States
  • Bakersfield Dermatology and Skin Cancer Medical Group Bakersfield, California, United States
View all 91 locations
View Trial Details
Completed

PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis

NCT01212757

Conditions
Arthritis, Arthritis, Psoriatic, Bone Diseases, +14 more
Locations
  • Clinical and Translational Research Center of Alabama, PC Tuscaloosa, Alabama, United States
  • Denver Arthritis Clinic Denver, Colorado, United States
  • New England Research Associates, LLC Trumbull, Connecticut, United States
  • Centre For Rheumatology, Immun. And Arthritis Fort Lauderdale, Florida, United States
View all 98 locations
View Trial Details
Completed

Open-Label,Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Preliminary Efficacy of CC1004 in Subjects With Severe Plaque Type Psoriasis

NCT00604682

Conditions
Psoriasis, Skin Diseases, Skin Diseases, Papulosquamous, +1 more
Locations
  • University of Medicine and Dentistry of New Jersey New Brunswick, New Jersey, United States
  • NYU School of Medicine New York, United States
  • Mt Sinai School of Medicine New York, United States
View Trial Details
Completed

Double-Blind, Randomized, Placebo-controlled Comparison of CC-10004 in Subjects With Moderate to Severe Plaque Type Psoriasis

NCT00606450

Conditions
Psoriasis, Skin Diseases, Skin Diseases, Papulosquamous, +1 more
Locations
  • Division of Dermatology and Cutaneous Science Edmonton, Alberta, Canada
  • Division of Dermatology Vancouver, British Columbia, Canada
  • Duronder C.P. Inc Moncton, New Brunswick, Canada
  • Eastern Canada Cutaneous Research Associates Halifax, Nova Scotia, Canada
View all 31 locations
View Trial Details
Completed

Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis

NCT02404350

Conditions
Arthritis, Arthritis, Psoriatic, Bone Diseases, +13 more
Locations
  • Novartis Investigative Site Upland, California, United States
  • Novartis Investigative Site Aurora, Colorado, United States
  • Novartis Investigative Site Denver, Colorado, United States
  • Novartis Investigative Site Brandon, Florida, United States
View all 172 locations
View Trial Details

Related conditions